Why cartilage damage after a tibial plateau fracture matters

A tibial plateau fracture breaks the upper surface of the shin bone — the part that forms the floor of the knee joint. Surgeons can realign and fix the bone, and X-rays may eventually confirm solid union, but a fracture that crosses the joint line almost always damages the cartilage lining at the same time. Once the bone has healed, that cartilage injury remains a separate, unresolved problem.

Articular cartilage — the smooth, load-bearing tissue that covers joint surfaces — has very limited capacity to repair itself. Unlike bone, it contains no blood vessels and relatively few cells capable of rebuilding damaged tissue. Focal defects left behind after fracture fixation rarely resolve spontaneously, regardless of how well the bone itself recovers.

Left unaddressed, a discrete chondral lesion of this kind can progress to post-traumatic osteoarthritis (PTOA): the exposed bone edges abrade surrounding tissue, low-grade inflammation accumulates, and the joint deteriorates over the following years. This is a well-recognised complication of tibial plateau fractures, not an inevitable consequence of ageing.

It is also worth understanding that not all residual cartilage damage is equivalent. A contained, discrete area of damage within an otherwise healthy joint — a focal defect — behaves differently from diffuse degeneration spread across the entire joint surface. That distinction shapes which interventions are appropriate and when they are best considered. Early identification of a focal defect is clinically meaningful precisely because the window for cartilage-targeted treatment is wider before generalised wear sets in.

What ChondroFiller injection is and how it works

ChondroFiller® — marketed in the UK as Liquid Cartilage™ — is a CE-marked Class III medical device manufactured by Meidrix Biomedicals GmbH. Its active material is a purified Type I collagen derived from murine tissue, supplied in liquid form and injected directly into the affected joint under ultrasound guidance as an outpatient procedure. No general anaesthetic or operating theatre is required.

Once placed inside the cartilage defect, the collagen liquid undergoes rapid in-situ polymerisation, forming a viscoelastic gel that conforms to the shape of the lesion and provides immediate mechanical cushioning between the damaged surfaces.

The more durable effect unfolds over the following weeks and months through a process called acellular matrix-induced chondrogenesis — in plain terms, the scaffold acts as a structured homing environment that draws the patient's own progenitor cells (from the synovial lining and subchondral bone beneath the defect) into the gel. These recruited cells gradually produce hyaline-like repair tissue within the scaffold rather than the inferior fibrocartilage that forms after simpler marrow-stimulation techniques.

Importantly, ChondroFiller® does not independently regrow cartilage. It supports the body's own repair processes by providing the structural and chemical cues that endogenous cells need to work effectively. The result is a single-stage, image-guided treatment that sits within a standard outpatient appointment rather than a surgical admission.

Which patients are typically assessed for this treatment

Suitability for ChondroFiller® rests on several factors that a specialist weighs together, rather than any single pass/fail criterion.

The nature of the defect is the first consideration. ChondroFiller® is designed for focal, contained Grade III or IV chondral lesions — areas where cartilage loss is localised to a discrete zone with healthy surrounding borders. Diffuse degeneration spread across the plateau as a whole falls outside this indication; the scaffold needs a defined cavity to fill and structurally sound surrounding tissue to integrate against.

Timing relative to fracture fixation also matters. Treatment is generally deferred until the tibial plateau fracture has achieved adequate bony stability, confirmed on imaging. A joint that is still consolidating around metalwork is not an appropriate environment for scaffold maturation.

Once fracture union is established and residual chondral damage has been characterised — typically on MRI or direct arthroscopic assessment — clinicians consider a wider set of patient-level factors. Surrounding cartilage quality, lower-limb alignment, and body mass index are each reviewed not as hard exclusion thresholds, but as variables that affect the mechanical environment the repair tissue will face once it has formed. Where significant malalignment is present, for instance, this may need to be addressed before or alongside cartilage treatment.

Patients with advanced, generalised osteoarthritis across the tibial plateau are generally less likely to benefit, since ChondroFiller® works on the principle of focal-defect containment — a principle that cannot apply when wear is widespread. A thorough consultation, including review of recent imaging and clinical examination, is the only reliable way to determine where an individual sits within these parameters.

What the clinical evidence shows

The strongest knee data come from four prospective studies, anchored by the Jerosch et al. post-market clinical follow-up (PMCF) cohort. At three-year follow-up, patients showed a mean IKDC score improvement of +32.4 points, reaching an average score of 80. To place that in context, the minimum clinically important difference (MCID) on the IKDC scale — the threshold below which patients do not reliably perceive a meaningful benefit — is 16.7 points. Published data indicate that ChondroFiller® consistently exceeds this threshold, and the gain appears stable rather than declining at the three-year mark.

Structural repair has been assessed alongside symptom change, using MOCART MRI scoring. European knee studies report MOCART scores of 81.6–84.3 at 12 months, indicating that more than 80% of the defect cavity is filled with repair tissue that integrates well with surrounding native cartilage. Progressive scaffold maturation is visible from as early as four weeks post-procedure. Across more than 19,000 cases performed globally, the reported complication rate is approximately 0% and the reoperation rate 3–8%.

The closest post-fracture analogue comes from Matta et al., who applied ChondroFiller® to residual chondral defects during arthroscopy-assisted fixation of intra-articular distal radius fractures. MRI follow-up confirmed reductions in bone marrow oedema, periarticular effusion, and joint-space narrowing. This is wrist evidence rather than knee evidence, and it is best read as proof-of-concept for the post-fracture delivery model — validating that the scaffold can be applied at the time of fracture management — rather than as direct data for the tibial plateau setting.

No published randomised trial has specifically studied ChondroFiller® in chondral defects arising from tibial plateau fracture. Evidence to date is drawn from the broader knee cartilage literature and the wrist post-fracture analogue. That gap is worth knowing, though it does not on its own determine individual suitability, which remains a matter for specialist assessment.

How ChondroFiller compares with other cartilage treatments

Choosing between cartilage treatments is rarely straightforward, and the right option depends on defect size, joint condition, and what the patient is trying to achieve — not on any single modality being universally superior.

Versus microfracture

Microfracture is the most commonly performed marrow-stimulation technique. By perforating the subchondral bone, it encourages blood and progenitor cells to fill the defect — but the tissue that forms is typically fibrocartilage rather than hyaline-like cartilage. Fibrocartilage is mechanically inferior, and published data suggest that functional gains after microfracture often decline between years two and three as the repair tissue degrades. Reoperation rates reach up to 41% in some series, compared with 3–8% across ChondroFiller® studies. ChondroFiller® promotes hyaline-like repair tissue through acellular matrix-induced chondrogenesis rather than blood-clot formation.

Versus ACI/MACI

Autologous chondrocyte implantation (ACI) and its matrix variant (MACI) are two-stage cell-based procedures. Published evidence shows IKDC improvements broadly comparable to those seen with ChondroFiller® (approximately 30–35 points), but ACI/MACI carries complication rates of up to 17% and reoperation rates of up to 37%. ChondroFiller® achieves similar functional gains in a single outpatient appointment.

Hyaluronic acid

Viscosupplementation with hyaluronic acid is a symptom-management option, not a structural repair. It does not address focal cartilage defects and is not a direct alternative for post-traumatic chondral lesions.

Corticosteroid injection

Corticosteroid is appropriate for managing acute inflammatory flares, but it is not a cartilage repair strategy. The McAlindon et al. 2017 JAMA randomised controlled trial documented progressive cartilage volume loss with repeated triamcinolone injections, which underlines the importance of limiting corticosteroid use where longer-term cartilage preservation is the goal.

A specialist will weigh defect size, containment, alignment, and patient age before recommending any of these pathways.

What to expect and how to find a specialist

Attending for ChondroFiller® injection follows a clear outpatient route. A specialist consultation comes first: recent MRI is reviewed to characterise the defect, surrounding cartilage quality and lower-limb alignment are assessed, and any outstanding mechanical factors are weighed before treatment is scheduled. If imaging is dated or the defect boundaries are unclear, an updated scan is typically arranged before a decision is made.

Treatment itself is an in-clinic appointment. The collagen scaffold is placed under ultrasound guidance using local anaesthetic; no theatre admission, sedation, or overnight stay is involved. Most patients leave the same day.

Recovery is graduated. Reduced or protected loading is usually advised in the early weeks while the scaffold begins to mature, with a progressive return to normal activity guided by the treating specialist. A follow-up MRI at around 12 months is standard practice to assess defect filling and integration — consistent with published studies showing that the bulk of scaffold maturation, as measured by MOCART imaging, occurs across this period.

Before any appointment, it is worth preparing specific questions: Does my defect size and containment fall within the treatment indication? Has lower-limb alignment been factored in? What does the follow-up imaging protocol look like? These shape how a consultation is used most efficiently and help set realistic expectations for the months ahead.

Guide costs vary between providers and should be confirmed directly with the treating clinic before proceeding. Search MSK lists specialists across the UK who offer ChondroFiller® injection for focal cartilage defects — filter by region and specialty to find a consultant suited to your situation.